miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2 Retraction in /10.3892/etm.2023.11801

Li,Mingfei; Yang,Yuan; Kuang,Yu; Gan,Xianfeng; Zeng,Wei; Liu,Yuping; Guan,Hua

doi:10.3892/etm.2017.4244

miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2

Retraction in: /10.3892/etm.2023.11801

Authors:
- Mingfei Li
- Yuan Yang
- Yu Kuang
- Xianfeng Gan
- Wei Zeng
- Yuping Liu
- Hua Guan
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610072, P.R. China, Health Management Center, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: March 20, 2017 https://doi.org/10.3892/etm.2017.4244
Pages: 2279-2285
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is currently ranked as the third leading cause of cancer-related mortality worldwide. microRNAs (miRs) serve important roles in the development and progression of HCC. miR‑365 has been demonstrated to function as a tumor suppressor in several types of cancer, including HCC; however, the mechanisms by which miR-365 regulates HCC apoptosis remains to be elucidated. In the present study, reverse transcription‑quantitative polymerase chain reaction was performed to determine miR‑365 expression levels in HCC and normal liver (LO2) cells. miR‑365 overexpression was induced in SMC7721 cells using a plasmid‑based system, and Cell Counting Kit‑8 and TUNEL assays were performed to detect cell activity and apoptosis following miR‑365 transfection. A luciferase assay was performed to determine the direct target of miR‑365 in apoptosis regulation. Furthermore, a subcutaneously transplanted tumor model was established to evaluate the effects of miR‑365 on tumor growth in vivo. The tumor tissue was used for further proliferation and apoptosis detection. The results of the present study indicated that miR‑365 expression was significantly lower in HCC cells compared with LO2 cells (P<0.01). Transfection of SMC7721 cells with miR‑365 plasmid significantly inhibited cell activity by inducing apoptosis (P<0.01). Luciferase assay indicated that miR‑365 targets B‑cell lymphoma 2 (Bcl‑2) directly and therefore induces the downstream expression of pro‑apoptotic proteins. The SMC7721 primary tumor growth was significantly reduced by miR‑365 transfection (P<0.01). Further investigation demonstrated that the miR‑365 group contained significantly fewer cells that were positive for proliferating cell nuclear antigen (P<0.01) and significantly more apoptotic cells (P<0.01). In conclusion, the results of the present study demonstrated that miR-365 may serve a role in inducing HCC apoptosis via directly targeting Bcl-2. This may provide a novel diagnosis and therapy target for the treatment of patients with HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ariff B, Lloyd CR, Khan S, Shariff M, Thillainayagam AV, Bansi DS, Khan SA, Taylor-Robinson SD and Lim AK: Imaging of liver cancer. World J Gastroenterol. 15:1289–1300. 2009. View Article : Google Scholar : PubMed/NCBI
3	Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, et al: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 137:110–118. 2009. View Article : Google Scholar : PubMed/NCBI
4	Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 56:1371–1383. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R and Rodés J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology. 27:1578–1583. 1998. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ambros V: microRNAs: Tiny regulators with great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
8	Anwar SL and Lehmann U: MicroRNAs: Emerging novel clinical biomarkers for hepatocellular carcinomas. J Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
9	He J, Zhao K, Zheng L, Xu Z, Gong W, Chen S, Shen X, Huang G, Gao M, Zeng Y, et al: Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer. 14:1632015. View Article : Google Scholar : PubMed/NCBI
10	Giordano S and Columbano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang XW, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology. 142:1431–1443. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hamada S, Masamune A, Miura S, Satoh K and Shimosegawa T: MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal. 26:179–185. 2014. View Article : Google Scholar : PubMed/NCBI
13	Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X and Han W: microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 33:220–225. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chen Z, Huang Z, Ye Q, Ming Y, Zhang S, Zhao Y, Liu L, Wang Q and Cheng K: Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma. Int J Clin Exp Pathol. 8:1705–1711. 2015.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 7:119962016. View Article : Google Scholar : PubMed/NCBI
17	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ghidini M and Braconi C: Non-Coding RNAs in primary liver cancer. Front Med (Lausanne). 2:362015.PubMed/NCBI
19	Wei R, Huang GL, Zhang MY, Li BK, Zhang HZ, Shi M, Chen XQ, Huang L, Zhou QM, Jia WH, et al: Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res. 19:4780–4791. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wong CM, Wong CC, Lee JM, Fan DN, Au SL and Ng IO: Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology. 55:1453–1461. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
22	Huang S and He X: The role of microRNAs in liver cancer progression. Br J Cancer. 104:235–240. 2011. View Article : Google Scholar : PubMed/NCBI
23	Salvi A, Abeni E, Portolani N, Barlati S and De Petro G: Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol. 42:391–402. 2013.PubMed/NCBI
24	Meng FL, Wang W and Jia WD: Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol. 31:1772014. View Article : Google Scholar : PubMed/NCBI
25	Ma Y, She XG, Ming YZ and Wan QQ: miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour Biol. 35:10731–10736. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lockshin RA and Williams CM: Programmed cell death-i. Cytology of degeneration in the intersegmental muscles of the pernyi silkmoth. J Insect Physiol. 11:123–133. 1965. View Article : Google Scholar : PubMed/NCBI
27	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
28	Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al: Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 17:61–75. 2013. View Article : Google Scholar : PubMed/NCBI
29	Qin B, Xiao B, Liang D, Xia J, Li Y and Yang H: MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expression. Biochem Biophys Res Commun. 410:127–133. 2011. View Article : Google Scholar : PubMed/NCBI